Jefferies Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St rises on cooler inflation data, big bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
H.C. Wainwright Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
October 24, 2024 7:43 AM EDTH.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $30.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA).
The analyst commented: "This morning, Olema presented three preclinical data posters at EORTC-NCI-AACR Symposium including combinations of OP-3136 with fulvestrant or palazestrant and/or CDK4/6 inhibitors, and combinations of palazestrant with everolimus (mTOR inhibitor) or capivasertib (pan-AKT inhibitor). As a reminder, OP-3136 is the company's KAT6 inhibitor, which is an emerging target for the treatment... More
Goldman Sachs Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
October 24, 2024 6:16 AM EDTGoldman Sachs analyst Richard Law reiterated a Buy rating and $27.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA).
The analyst comments "At the EORTC-NCi-AACR Symposium, OLMA presented preclinical in vitro and in vivo results for its KAT6 inhibitor OP-3136 vs. PFE's PF-07248144 as monotherapy, or in various doublet/triplet combinations with endocrine therapy (fulvestrant or pala) and/or CDK4/6i (ribociclib). For the... More
